HSIC — Henry Schein, Inc.

Summary of Henry Schein, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Sales: Global sales reached $3.4 billion, reflecting a 7.7% increase year-over-year, with constant currency growth of 5.8%.
• Net Income: GAAP net income was $101 million ($0.85 per diluted share), up from $94 million ($0.74 per diluted share) in Q4 2024. Non-GAAP net income was $160 million ($1.34 per diluted share), compared to $149 million ($1.19 per diluted share) in the prior year.
• Operating Margin: GAAP operating margin was 4.76%, a slight decline from the previous year, while non-GAAP operating margin was 7.42%, relatively flat year-over-year.
• Adjusted EBITDA: For 2025, adjusted EBITDA was $191 million.

2. Strategic Updates and Business Highlights

• BOLD+1 Strategic Plan: The company is on track to exceed its goal of having over 50% of operating income from high-growth, high-margin businesses by 2027.
• E-commerce Rollout: The global e-commerce platform, henryschein.com, is being rolled out, with completion expected for U.S. dental and Canadian customers in Q1 2026.
• Product Innovations: Launched exclusive products like Novartis' Curaden for early-stage caries detection and partnered with Amazon Web Services for AI integration.
• Market Performance: Strong sales growth in global distribution, specialty products, and technology sectors, with notable performance in U.S. dental equipment and international markets.

3. Forward Guidance and Outlook

• 2026 Sales Growth: Expected sales growth of 3% to 5% over 2025.
• Earnings Guidance: Non-GAAP diluted EPS projected to be between $5.23 and $5.37, reflecting a growth of 5% to 8% compared to 2025.
• Value Creation Initiatives: Anticipated annual run-rate operating income improvement of over $125 million by 2026 from ongoing initiatives.

4. Challenges and Points of Concern

• Operating Margin Pressure: The company faces challenges with gross margins due to a shift in product mix, particularly with lower-margin value implants growing faster than premium implants.
• Medical Business Risks: Potential headwinds from declining respiratory product demand and uncertainty surrounding ACA subsidies impacting procedure volumes.
• Cybersecurity Recovery: While the company has moved past its cybersecurity incident, there are lingering effects on customer engagement and market dynamics.

5. Notable Q&A Insights

• Market Stability: Management expressed confidence in the stability of the dental market, with positive sentiment among dentists regarding investments in technology.
• Value Creation Initiatives: The $125 million run-rate contribution from value creation initiatives is expected to be weighted towards the second half of 2026, with some initial headwinds anticipated.
• Implant Market Dynamics: The specialty products segment is expected to grow in the high-single digits, with international markets showing stronger growth than the U.S.

Overall, Henry Schein, Inc. reported strong financial results for Q4 2025, driven by strategic initiatives and market momentum, while also navigating challenges related to margin pressures and market dynamics. The leadership transition to Fred Lowry is anticipated to further enhance growth strategies.